)
Vangipuram Rangan
Vice President, Protein Sciences & Early CMC,
CytomX Therapeutics
- Extensive experience in discovery and development of antibody and antibody drug conjugate (ADC) therapeutics for oncology, immuno-oncology and immunology targets.
- Expertise in building and managing a state-of-the-art protein expression, production, purification, analytical and bioanalytical labs and teams that are on par with the best in industry to contribute to the development of therapeutic biologics candidates.
- Successfully have transitioned more than 15 antibody therapeutics and 3 ADCs from discovery to IND for oncology, IO and immunology assets including approved drug Opdivo. • Expertise in developing and implementing analytical and bioanalytical strategies and assays to support preclinical biologics development and PK/PD efforts.
- Functioned as a liaison between Discovery and Development group for therapeutic antibody and ADC programs.
- Experienced in writing SOPs and protein chemistry sections for IND filings.
- Experienced in evaluating and working with CROs and CMOs